Janssen

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.

GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.

Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.

Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.

The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.

The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.

The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.

Pages

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.